Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dependent-Kinase-1 (Cdc2) Inhibitor, in Patients

  • McDonagh, Kevin (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date1/18/08 → 8/31/09